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900Shuttering of the superior mesenteric artery during
fenestrated endovascular aneurysm repair
Brant W. Ullery, MD, George K. Lee, MD, and Jason T. Lee, MD, Stanford, Calif
Objective: Shuttering occurs when a scallop or fenestration does not align perfectly with the target vessel ostium and is
potentially minimized by stenting. The current United States Food and Drug Administration-approved fenestrated
endovascular aneurysm repair (f-EVAR) device is most commonly conﬁgured with an unstented superior mesenteric
artery (SMA) scallop, thereby subjecting the SMA to risk of partial coverage. We aimed to describe the incidence, severity,
and clinical effect of SMA shuttering during f-EVAR.
Methods: Patients undergoing f-EVAR using the commercially available Zenith (Cook Medical, Bloomington, Ind)
fenestrated stent graft system containing an SMA scallop at our institution between September 2012 and January 2014
were included for analysis. Corrected multiplanar reformatted images on postoperative computed tomographic angiog-
raphy were reviewed to measure SMA shuttering, deﬁned as the percentage of scallop misalignment relative to the SMA
ostial diameter.
Results: Of the 28 f-EVAR cases performed at our institution during the study period, 18 patients (78% male) had
an SMA scallop and were included in this analysis. The median age was 78 years (interquartile range [IQR],
72-81 years), and the median abdominal aortic aneurysm size was 61 mm (IQR, 56-64 mm). Fifty-one vessels were
targeted (18 SMA scallops, 32 renal fenestrations, 1 renal snorkel), with covered stents placed in all fenestrations.
Target vessel catheterization and successful branch stent deployment was achieved in 100% of patients. SMA shut-
tering measured on postoperative computed tomographic angiography of any amount occurred in 50% of patients
(range of SMA shuttering, 12%-40%). The severity of SMA shuttering varied: one patient had 11% to 20%, four had
21% to 30%, and four had 31 to 40%. When compared with patients without shuttering, patients with any SMA
shuttering were noted to have a shorter infra-SMA neck length (17 vs 25 mm; P [ .007), higher volume of intra-
procedural contrast administration (100 vs 66 mL; P [ .001), and had a trend toward longer procedural durations
(240 vs 188 minutes; P [ .09). No association was found between SMA shuttering and the preoperative measured
clock position of the visceral vessels, percentage of device oversizing, number of target vessels per patient, aortic
diameter at the SMA or seal zone, aneurysm neck morphology, infrarenal neck length, scallop width, or SMA ostial
diameter. No acute or chronic events of mesenteric ischemia were noted during a median clinical follow-up period of
11 months (IQR, 5-14 months).
Conclusions: Even with the custom design of currently available fenestrated technology, shuttering of the SMA occurred in
one-half of the patients in our cohort, although no clinical events were noted. Further details of the incidence, magnitude,
and tolerance of SMA shuttering during f-EVAR are warranted to fully understand the clinical implication of this
radiographic ﬁnding. Future design considerations for advanced EVAR should take into account SMA shuttering to
further reﬁne operative planning. (J Vasc Surg 2014;60:900-7.)Fenestrated endovascular aneurysm repair (f-EVAR)
represents an innovative and technically demanding
approach to the treatment of short-neck and juxtarenal
abdominal aneurysms (JAAs). Although f-EVAR was ﬁrst
reported in 1999,1 experience in the United States (U.S.)
remains in its relative infancy, with relatively few centers
having access to the clinical trials or investigational device
exemption-sponsored trials. Only after the recent approval
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://dx.doi.org/10.1016/j.jvs.2014.04.055aortic aneurysm (AAA) device (Cook Medical, Blooming-
ton, Ind) by the U.S. Food and Drug Administration in
April 2012 has increasing experience been reported in the
U.S., with a number of published series demonstrating
favorable early and midterm results using this advanced
EVAR technique.2-5
Shuttering occurs when a scallop or fenestration does
not align perfectly with the target vessel ostium and is
potentially minimized by the use of stenting. The term
shuttering has not been previously described nor quantiﬁed
in the literature, and theoretically could range from 0%
(perfect alignment) to 100% (complete coverage of the
scallop/fenestration). The currently approved f-EVAR
platform is most commonly constructed with an unstented
superior mesenteric artery (SMA) scallop, thereby subject-
ing the SMA to the risk of partial coverage during device
deployment.
Although poorly deﬁned and not mentioned to any
signiﬁcance in the literature, the theoretical clinical
sequelae of SMA shuttering would be branch vessel
ischemia and possible visceral malperfusion. Adverse events
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ranging from entirely asymptomatic to the development
of life-threatening mesenteric ischemia. In the world’s
largest experience with f-EVAR from the Cleveland Clinic,
concern was raised recently about unsupported scallops at
the SMA, and a recommendation was offered to stent all
scallop conﬁgurations.5 Given the extreme paucity of imag-
ing data regarding shuttering during complex aneurysm
repair, we aimed to describe the incidence, severity, and
clinical impact of SMA shuttering during f-EVAR.
METHODS
Patients and inclusion criteria. The present study
included a retrospective review of all consecutive patients
with complex AAAs treated by f-EVAR using the commer-
cially available ZFEN endovascular AAA endograft at our
institution between September 2012 and January 2014.
All patients were enrolled in our complex EVAR protocol
approved by our local Institution Review Board and
informed consent was obtained from all patients. Aneurysm
extent included short-necked infrarenal, juxtarenal, para-
renal, and type IV thoracoabdominal aortic aneurysms.
All patients were considered medically or anatomically
unsuitable for conventional EVAR. Only patients under-
going f-EVAR with a main body device containing a
SMA scallop and those with available postoperative cross-
sectional imaging were included for analysis. Exclusion
criteria included any procedure involving a fenestrated
device constructed without an SMA scallop, as well as
any f-EVAR associated with SMA stenting or use of a peri-
scope or snorkel technique involving the SMA. Also excluded
were patients without available postoperative imaging.
Device description. The ZFEN endovascular device
has a modular design consisting of two primary compo-
nents: a proximal main body graft and a distal bifurcated
main body graft that often requires at least one iliac limb
extension to complete most procedures. Each component
is composed of full-thickness woven polyester fabric and
self-expanding stainless steel stents that are secured
together as a composite endograft using braided polyester
and monoﬁlament polypropylene suture. The proximal
main body component may accommodate a combination
of up to three fenestrations or scallops, thereby maintaining
visceral arterial patency and facilitating a more proximal
sealing position compared with standard EVAR devices.
The two most common endograft conﬁgurations involve
one scallop or fenestration for an asymmetrically vertically
positioned renal artery or two renal fenestrations and one
scallop for the SMA.
A scallop represents a U-shaped gap within the prox-
imal fabric of the stent graft; all scallops are 10-mm wide
and 6-mm to 12-mm in height, custom ordered by the
implanting physician, with the most common choice being
a 12-mm height. In contrast, fenestrations are circular or
elliptical holes within the proximal main body fabric. The
fenestrations are either small with an elliptical shape
(6-mm width and a height of 6 or 8 mm) and ﬁt entirely
between the struts of the seal stent or are large with acircular shape (diameters measuring 8, 10, or 12 mm)
that when constructed do cross struts of the seal stent. In
accordance with the instructions for use for this device, it
is recommended that all vessels accommodated by a small
fenestration be stented to optimize and secure proper
alignment of the fenestration with the ostium of the
visceral vessel. Stenting for vessels accommodated by a
scallop is optional and not recommended in vessels accom-
modated by a large fenestration.
Technical details regarding implantation of fenes-
trated endovascular AAA devices have been previously
described.2,6,7 In brief, the technique begins preoperatively
with custom design of the scallop and fenestrations relative
to clock positions and at chosen distances from the proximal
edge of fabric. During the actual procedure, the proximal
main body is introduced, with proper rotational orientation
conﬁrmed by the overlap of an anterior row of vertical and
posterior row of horizontal markers to form a cross. Correct
orientation is also conﬁrmed with reference to the circum-
ferential radiopaque markers of the renal fenestrations and
SMA scallop, and in our practice lined up with prewired
renal vessels.8 Selective catheterization of the target visceral
vessels is performed at this time and conﬁrmed using a small
injection of contrast medium. Sheaths are advanced into all
target vessels, and stents are prepositioned within the
sheaths, where applicable, before endograft deployment.
Our practice is to place covered stents within target
vessels accommodated by small fenestrations. We do not
routinely stent target vessels accommodated by scallops
or large fenestrations. The proximal main body graft is
deployed at this time and balloon-molded to the juxtarenal
neck. The visceral stents are then deployed and ﬂared
approximately one-third of the stent graft length (usually
w5 mm) within the aortic lumen to enhance ﬁxation and
minimize risk of endoleak. Completion angiography after
assembly and deployment of all modular components is
performed to document target vessel patency and presence
of any endoleak.
Calculation of SMA shuttering. High-resolution
computed tomographic angiography (CTA) of the
abdomen and pelvis was obtained in all patients preopera-
tively and #30 days postoperatively. Additional postopera-
tive imaging at 6 and 12 months, and annually thereafter,
was pursued unless prohibited by severe renal insufﬁciency,
in which case duplex ultrasound imaging and noncontrast
CT was substituted.
A dedicated three-dimensional workstation (TeraRe-
con, San Mateo, Calif) with semiautomated centerline of
ﬂow reconstruction was used to characterize visceral
segment geometry. Corrected multiplanar images from
postoperative scans were reviewed as a group by all three
authors to measure the degree of SMA shuttering, deﬁned
as the percentage of scallop misalignment relative to the
SMA ostial diameter (Fig 1). The position of the scallop
relative to the ostium of the SMA was veriﬁed in coronal
and sagittal orientations, and misalignment was often
most notable in the lateral direction, although we did not
speciﬁcally measure vertical shuttering. The craniocaudal
Table I. Baseline patient characteristics
Variable Median (IQR) or No. (%)
Demographics
Age, years 78 (72-81)
Male gender 14 (78)
Comorbidities
Hypertension 16 (89)
Stroke 3 (17)
Coronary artery disease 12 (67)
Arrhythmia 5 (28)
Prior myocardial infarction 8 (50)
Dyslipidemia 15 (83)
Chronic renal insufﬁciencya 6 (33)
COPD 8 (50)
Oxygen-dependent COPD 2 (11)
Peripheral vascular disease 7 (39)
Congestive heart failure 8 (50)
Diabetes 2 (11)
Tobacco use 11 (61)
Prior aortic surgery 2 (11)
COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.
aDeﬁned as creatinine $1.5 mg/dL.
Fig 1. Shuttering of the superior mesenteric artery (SMA) is
calculated as the amount of scallop misalignment (short white
arrow, A) relative to the SMA ostium divided by the width of the
scallop (longer white arrow, B).
Table II. Anatomic data
Variable
No. (%) or median (IQR)
(n ¼ 18)
Extent of aneurysm
Juxtarenal 16 (89)
Pararenal 1 (6)
Type IV thoracoabdominal 1 (6)
Maximum aortic diameter, mm 61 (56-64)
Infra-SMA neck length,a mm 23 (19-26)
Aortic diameter, mm
At celiac artery 25 (23-28)
At SMA 24 (21-26)
At most caudal renal artery 22 (20-28)
IQR, Interquartile range; SMA, superior mesenteric artery.
aLength of sealing zone below the SMA.
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tive to the SMA was also calculated.
Also recorded were baseline patient demographics and
perioperative data, including procedure duration, ﬂuoros-
copy time, contrast volume use, estimated blood loss,
aneurysm morphology, type and conﬁguration of fenes-
trated device, length of stay, presence of endoleak, target
vessel patency, complications, and need for reintervention.
Comparison of these clinical and radiographic variables was
subsequently performed after stratifying for the presence or
absence of SMA shuttering.
Deﬁnitions. A target vessel was deﬁned as any vessel
that was selectively catheterized and incorporated into
the proximal main body device conﬁguration, including
all those vessels accommodated by a fenestration or a
scallop. Target vessel patency was deﬁned as absence of
target vessel stenosis or occlusion requiring reintervention
during the follow-up period. Target vessel events
included target vessel stenosis or occlusion, need for any
reintervention, or aneurysm sac growth secondary to
branch-related type III endoleak. Reintervention was
deﬁned as a repeat procedure for complications that were
related to the aneurysm or endograft or a result of the
initial procedure. Early mortality included deaths occurring
during the index hospitalization or #30 days after the
procedure. Preoperative renal insufﬁciency was deﬁned as
serum creatinine values $1.5 mg/dL. Postoperative renal
impairment was deﬁned as a 50% increase in creatinine
value compared with preoperative baseline values.
Statistical analysis. Comparative analysis of categoric
variables was performed using the c2 or Fisher exact test
when appropriate. Continuous variables were analyzed
using the Student t-test or Mann-Whitney test when
appropriate and are expressed as the mean 6 standard de-
viation or median plus interquartile range (IQR), depending
on the distribution of data. All P values were two-sided, and
P values of <.05 were considered statistically signiﬁcant.RESULTS
Overall study cohort. Of 28 f-EVARs performed dur-
ing the study period, 18 patients (78% male) had an SMA
scallop and therefore met study criteria for analysis. Ten
patients were excluded because of implantation of a device
not conﬁgured with a scallop (n ¼ 7), absence of available
thin-slice postoperative imaging (n ¼ 2), or stenting of an
SMA scallop as part of a periscope technique (n ¼ 1).
Patients who met the inclusion criteria were a median age
of 78 years (IQR, 72-81 years). Baseline patient charac-
teristics are reported in Table I.
All procedures were performed electively under gen-
eral anesthesia for the treatment of asymptomatic
aneurysms. Rapid aneurysmal expansion as an indication
for surgery was noted preoperatively in one patient.
Median maximum transverse aortic diameter was 61 mm
(IQR, 56-64 mm), with 89% of cases involving a JAA. Addi-
tional anatomic data for the study cohort are noted in
Table II.
Table III. Targeted visceral vessels
Vessel
Scallops,
No.
Fenestrations
Snorkel,
No.
Total,
No.
Small,
No.
Large,
No.
Celiac artery 0 0 0 0 0
SMA 18 0 0 0 18
Renal arteries
Right 0 16 0 1 17
Left 0 16 0 0 16
Accessory 0 0 0 0 0
Total 18 32 0 1 51
SMA, Superior mesenteric artery.
Table IV. Visceral vessel clock position and distance
relative to superior mesenteric artery (SMA)
Vessel
Clock position,
median (range)
Distance from the SMA,a
median (range), mm
Celiac artery 12:30 (11:30-2:30) 20 (12-27)
SMA 12:15 (11:30-1:45)
Renal arteries
Left 2:45 (1:30-4:15) 12 (5-22)
Right 9:45 (9:00-11:30) 11 (3-21)
aDistance relative to inferior margin of SMA ostium.
Table V. Procedural data and 30-day perioperative
outcomes
Variable No. (%) or median (IQR) (n ¼ 18)
Procedural duration, minutes 180 (169-248)
Estimated blood loss, mL 500 (300-750)
Fluoroscopy time, minutes 72 (53-95)
Contrast media dose, mL 84 (63-99)
Blood transfusion, units 0 (0-0.8)
Adjunctive procedure
Iliac conduit 4 (22)
Iliofemoral bypass 2 (11)
Femoral endarterectomy 2 (11)
Complications
Death 1 (6)
Myocardial infarction 1 (6)
Respiratory failure 0 (0)
Bowel ischemia 0 (0)
Spinal cord ischemia 0 (0)
Renal failure 3 (17)
Technical events
Cannulation failure 0 (0)
Malposition of endograft 0 (0)
Endoleak type I or III 1 (6)
Target vessel
Injury or dissection 0 (0)
Thrombosis 1 (6)
Stenosis 1 (6)
Reintervention
Early, <30 days 1 (6)
Late 1 (6)
Length of stay, days 4 (3-6)
IQR, Interquartile range.
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0.43 per patient; Table III). By deﬁnition, all fenestrated
stent graft conﬁgurations in this cohort included the pres-
ence of an SMA scallop; 14 patients had two fenestrations,
and four patients had one fenestration (presence of single
renal artery occlusion, n ¼ 3; snorkel technique involving
contralateral renal artery, n ¼ 1). The median SMA clock
position was 12:15 (range, 11:30-1:45). The median clock
position and distance of other visceral vessels relative to the
reference celiac position are noted in Table IV.
Successful target vessel catheterization and stenting
was achieved in 100% of patients. Procedural data and
30-day perioperative outcomes are listed in Table V. Clin-
ical follow-up was a median of 11 months (IQR,
5-14 months), and a ﬁrst-month postoperative CTA was
available for review in all patients. The postoperative
CTAs demonstrated an endoleak in ﬁve patients (type II,
n ¼ 4; type III, n ¼ 1). There were no mesenteric ischemic
events.
One death at 30 days occurred in a 67-year-old man
with a history of ischemic cardiomyopathy and congestive
heart failure who underwent f-EVAR for an asymptomatic
9-cm JAA. This patient had an uneventful hospital course
and was discharged home on postoperative day 4. He sus-
tained a myocardial infarction w2 weeks later and died
shortly thereafter. One late death occurred in a 74-year-
old woman with a 5.8-cm JAA who underwent a successful
f-EVAR requiring an iliac conduit and iliofemoral bypass
procedure secondary to small access vessels. She had an un-
remarkable postoperative course and was discharged home
on postoperative day 6. The patient died of a primary car-
diac event 5 months postoperatively.
The 30-day target vessel primary patency was 98.0%
(50 of 51), with one additional renal vessel occluding in
midterm follow-up for a primary patency of 96.1%
(follow-up range, 3-18 months). There were no target
vessel events or reinterventions related to the SMA during
the follow-up period; however, reinterventions were per-
formed in two patients (11.1%) as a result of renal target
vessel events. The ﬁrst procedure involved an early rein-
tervention on postoperative day 2 for an occluded left
renal artery stent in the setting of acute renal failure.
Restoration of renal arterial patency was achieved afterpercutaneous mechanical and pharmacologic thromboly-
sis and placement of an additional covered stent. The
second reintervention was performedw3 months postop-
eratively in a patient noted to have kinking of a left renal
artery stent and an associated endoleak at the junction of
the renal stent and main body fenestration. This was suc-
cessfully treated with balloon angioplasty to gain full wall
apposition to the fenestration and reﬂaring of the covered
stent.
SMA shuttering. Shuttering of the SMA of any
amount occurred in 50% of patients (range, 12%-40%).
The severity of SMA shuttering varied: one patient had
11% to 20%, four had 21% to 30%, and four had 31% to
40% (Fig 2). The distribution of SMA shuttering varied
Fig 2. Distribution of superior mesenteric artery (SMA) shutter-
ing severity. Fig 3. Distribution of superior mesenteric artery (SMA) shutter-
ing during the course of the study period, 2012 to 2014.
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All celiac and SMA vessels were patent on postoperative
imaging.
On univariate analysis, patients with SMA shuttering
were noted to have a shorter infra-SMA neck length (17
vs 25 mm; P ¼ .007), a higher volume of intraprocedural
contrast administration (100 vs 66 mL; P ¼ .001), and
had a trend toward longer procedural durations (240 vs
188 minutes; P ¼ .09). No association was found between
SMA shuttering and the measured clock position of the
visceral vessels, percentage of device oversizing, number
of target vessels per patient, aortic diameter at the SMA
or seal zone, aneurysm neck morphology (infrarenal and
infra-SMA neck length, aortic diameter at seal zone),
infrarenal neck length, scallop width, or SMA ostial diam-
eter. SMA shuttering was not associated with any increased
risk of postoperative complications, length of stay, or need
for secondary reintervention (Table VI). No acute or
chronic events of mesenteric ischemia were observed dur-
ing the course of the clinical or radiographic follow-up
periods.
DISCUSSION
Although worldwide experience with fenestrated stent
graft technology is entering its second decade, knowledge
regarding the long-term durability of this technique rela-
tive to successful aneurysm exclusion and target vessel
patency has yet to be fully elucidated. In the present study,
we analyzed the incidence, severity, and clinical effect of
SMA shuttering observed in radiographic imaging after f-
EVAR and found one-half of patients experienced SMA
shuttering, ranging in severity from 12% to 40%. No clin-
ical events or reinterventions were related to SMA
shuttering.
The 50% incidence of SMA shuttering detected in our
cohort was rather surprising, particularly given the
perceived intricacy of preoperative case planning, precision
of device conﬁguration, and the fortunate absence of any
clinically apparent mesenteric ischemia. The conduct and
case preparation of f-EVAR is certainly more complexthan conventional EVAR. Moreover, the shorter infra-
SMA neck length and increased procedural time and
contrast media dose noted in the cases involving SMA
shuttering may serve as a surrogate for cases requiring addi-
tional technical demands. The three-dimensional software
used to generate multiplanar reconstructions with center-
line measurements represents a critical component of the
preoperative evaluation process and is essential for
achieving successful device implantation.8
Current industry-sponsored training programs in the
U.S. require the presence of an experienced proctor in
the technical aspects of f-EVAR to assist the ﬁrst two cases
for any physician. Indeed, the distribution of SMA shutter-
ing observed in our experience over time, as highlighted in
Fig 3, might suggest that a learning curve must be taken
into account, given that 78% of cases involving SMA shut-
tering occurred in the ﬁrst half of our experience with f-
EVAR. Despite a limited study period spanning only
17 months, the fact that our experience with f-EVAR
over time was able to yield a convincing trend toward radi-
cally decreased SMA shuttering lends further support for a
preoperative case planning or intraprocedural technical
causal factor rather than an inherent device design or tech-
nique ﬂaw or malfunction.
A similar ﬁnding related to the importance of SMA
scallop positioning and possible learning curve issues was
observed by Verhoeven et al6 in their 8-year single-center
experience using f-EVAR for the treatment of short-
necked infrarenal and JAAs. Their report included 275
target vessels in 160 patients, including 106 scallops (celiac,
n¼ 5; SMA, n¼ 74; renal, n ¼ 27). Target vessel occlusion
occurred in 12 patients (7.5%), each occurring #2 years
of f-EVAR. Three of the 12 patients with target vessel
occlusion involved an unstented scallop (SMA, n¼ 1; renal,
n ¼ 2), and each occlusion was attributed to device malpo-
sitioning. The isolated SMA occlusion in their series
occurred 2 months postoperatively and, unlike the remain-
ing 11 cases involving renal artery occlusion, was entirely
asymptomatic. The authors concluded that a learning curve
effect could partially explain the fact that all target vessel
occlusions occurred within the ﬁrst 2 postoperative years,
Table VI. Procedural data and postoperative outcomes between patients with and without superior mesenteric artery
(SMA) shuttering
Variable
SMA shuttering
P
Present (n ¼ 9), Absent (n ¼ 9),
mean 6 SD or No. (%) mean 6 SD or No. (%)
Age, years 74.9 6 8.3 76.6 6 5.5 .62
Procedural data
Procedural duration, minutes 240.0 6 77.9 187.8 6 36.5 .09
Estimated blood loss, mL 616.7 6 390.5 433.3 6 210.7 .23
Fluoroscopy time, minutes 91.3 6 45.2 66.5 6 28.6 .18
Contrast medium dose, mL 100.4 6 19.9 65.8 6 17.5 .001
Complications
Death 0 (0) 1 (11) 1.0
Myocardial infarction 1 (11) 0 (0) 1.0
Respiratory failure 0 (0) 0 (0) 1.0
Bowel ischemia 0 (0) 0 (0) 1.0
Spinal cord ischemia 0 (0) 0 (0) 1.0
Renal failure 2 (22) 1 (11) 1.0
Length of stay, days 7.1 6 6.2 4.0 6 1.3 .16
Reintervention 2 (22) 0 (0) .47
Anatomic data
Infra-SMA neck length, mm 17.4 6 6.5 25.2 6 3.8 .007
Infrarenal neck length, mm 3.9 6 3.6 4.6 6 3.1 .68
Maximum diameter at seal zone, mm 25.6 6 4.8 24.6 6 3.4 .62
Maximum aortic diameter, mm 60.9 6 7.5 62.7 6 16.0 .77
Scallop width, mm 8.3 6 1.5 8.5 6 1.6 .78
SMA ostial diameter, mm 9.8 6 2.0 9.9 6 2.4 .94
Aortic diameter at SMA, mm 24.1 6 3.6 23.7 6 3.6 .79
Device oversizing, % 16.4 6 5.7 18.4 6 4.2 .41
SMA shuttering, % 31.6 6 12.0 0 <.0001
Target vessels per patient, No. 2.7 6 0.5 2.9 6 0.3 .28
SMA clock position .22
11:00-11:45 1 (11) 3 (33)
12:00-12:45 6 (67) 6 (67)
1:00-1:45 2 (22) 0 (0)
SD, Standard deviation.
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ered mandatory at the later part of their experience. One-
half of the occlusions in their experience involved an
unstented scallop (n ¼ 3) or fenestration (n ¼ 3).
Moreover, the early generation ZFEN device featured
a nonreinforced scallop that was predisposed to folding
and narrowing. Subsequent device modiﬁcation has since
incorporated a double-ring reinforcement to the design
of all scallops to ameliorate this risk of narrowing.
Although the current-generation ZFEN device features
a reinforced scallop, the decision whether to stent a scallop
remains controversial. Indeed, similar to the rationale for
routine stenting of renal artery fenestrations, it would
seem logical that stenting of scallops would similarly
decrease the potential for SMA shuttering by forcing the
scallop into alignment with the target SMA. The instruc-
tions for use of the ZFEN device offer no speciﬁc recom-
mendation pertaining to this technical aspect of the
procedure, stating that stenting for vessels accommodated
by a scallop is optional. No data are available to date that
speciﬁcally examine the effect of stenting a scallop on target
vessel patency.In one of the largest experiences to date, Mastracci
et al5 recently reported the long-term results of 650 pa-
tients undergoing EVAR with branched or fenestrated de-
vices between 2001 and 2010. Secondary procedures were
performed for 0.6% of celiac, 4% of SMA, 6% of right renal,
and 5% of left renal artery stents. Reinterventions for SMA
stents occurred in 26 patients, with one-half involving an
endoleak and the remaining one-half involving stenosis or
thrombosis. Only nine of these patients presented with ur-
gent or symptomatic complications related to SMA malper-
fusion. Three deaths occurred as a result of target vessel
events, including two from acute SMA in-stent thrombosis
and one from an unstented SMA scallop. The authors
noted that this death from an unstented SMA scallop
served as their ﬁrst death as a result of a branch vessel-
related complication and has since guided their institu-
tional practice to treat SMA scallops like fenestrations
with routine stenting. We remain unconvinced, based on
one unstented scallop in a 10-year experience by experts
leading to a death, that all scallops should be stented.
There is a paucity of outcomes related to the natural
history of stented SMA scallops. However, complications
JOURNAL OF VASCULAR SURGERY
906 Ullery et al October 2014from stented SMA fenestrations have been reported,
including two of the three deaths in the series by Mastracci
et al.5 Fracture of stents within SMA fenestrations have also
been described.9
Our suspicion of etiologies for SMA scallops leading to
ischemia was heightened by the Cleveland Clinic report,
and led us to measure the shuttering that seemed to be an
inherent risk in custom designed endografts. The current
study represents the ﬁrst report to quantitatively and qualita-
tively deﬁne SMA shuttering after f-EVAR.Despite the wide
range of SMA shuttering observed in our cohort, no mesen-
teric ischemic events occurred throughout the follow-up
period. Given the inherent limitations of a small retrospec-
tive cohort study and the short follow-up time, the true clin-
ical effect of the presence and severity of SMA shuttering
requires additional investigation. Native SMA or SMA in-
stent stenosis/occlusion may be clinically silent or lead to
catastrophic bowel necrosis. The critical value of SMA shut-
tering needed to produce clinical evidence of mesenteric
ischemia is likely patient-dependent and may be inﬂuenced
by the status of mesenteric collateral circulation as well as
the magnitude and acuity of visceral malperfusion.
SMA shuttering is not yet a widely reported phenome-
non, and as a result, the clinical effect of this entity may
only be loosely extrapolated from studies reporting SMA
target vessel events. The related but separate inﬂuence of
periprocedural SMA embolization or dissection must also
be taken into account when comparing across studies and
forms of target vessel complications. Banno et al10
described their experience with 80 patients undergoing
f-EVAR. They noted a 2.5% incidence of early postopera-
tive mesenteric ischemia, and 5% of patients underwent
reinterventions related to signs or symptoms of mesenteric
ischemia (3.8% early and 1.3% late). The clinical outcome
of those developing or requiring reintervention for acute
mesenteric ischemia was not speciﬁed.
In their experience with 107 patients undergoing
branched or f-EVAR, Troisi et al11 reported three target
vessel events involving the SMA. One patient presented
2 months postoperatively with celiac artery and SMA
in-stent occlusions and ultimately died of prolonged bowel
necrosis and multiorgan failure after an unsuccessful endo-
vascular recanalization attempt. The two remaining postop-
erative events in this series occurred at 11 months and
17 months, with both involving symptomatic SMA in-
stent stenosis characterized by abdominal pain. Bothpatients
were successfully treated with the placement of a SMA stent.
In the long-term follow-up of 54 patients treated with
f-EVAR by Kristmundsson et al,12 target vessel occlusion
occurred in 10.7% of unstented SMA scallops at 6 to
12 months postoperatively. All patients were asymptomatic
and required no further intervention. In one additional
patient, an asymptomatic SMA stenosis was detected at
the 6-year follow-up and was successfully stented (3.6%
of unstented SMA scallops).
Recent development of the Zenith p-branch off-the-
shelf fenestrated device offers an additional angle of com-
parison pertaining to target vessel patency. This deviceallows incorporation of the renal arteries and SMA using
fenestrations and the celiac artery within a scallop. The
incorporation of the SMA within a fenestration was con-
structed to permit a longer segment of circumferential
aortic sealing, a modiﬁcation prompted by the frequent
recognition of visceral segment ectasia that is predisposed
to longitudinal progression. Inadequate visceral aortic
segment incorporation serves as a common mode of stent
graft failure and has been associated with migration and
proximal endoleak owing to longitudinal progression of
aneurysmal disease. The effect of this design modiﬁcation
on target vessel patency appears to be quite favorable
thus far. Kitagawa et al13 reported the early clinical out-
comes with this device in 16 patients and noted only one
late target vessel occlusion involving a renal artery.
CONCLUSIONS
Even with the custom design of current FDA-approved
fenestrated technology, we observed shuttering of the
SMA occurred in one-half of patients, although no clinical
events were noted. The brief follow-up period represents a
limitation to the present study, and thus, further investiga-
tion is warranted to assess the natural history of SMA shut-
tering over a longer follow-up period as well as to evaluate
for potential of late radiographic or clinical events related
to SMA patency. Moreover, additional study of the inci-
dence, severity, and tolerance of SMA shuttering during
f-EVAR is warranted to fully understand the clinical impli-
cation of this radiographic ﬁnding. Future design consider-
ations for advanced EVAR should take into account SMA
shuttering to further reﬁne operative planning and opti-
mize patient outcomes.
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